Recent & Archived News
April 05, 2018
Bayer to Showcase Data from Diverse Oncology Pipeline at AACR 2018
Bayer will present research from its growing oncology portfolio at the American Association for Cancer Research (AACR) 2018 Annual Meeting, taking place April 14-18 in Chicago. These presentations...
March 26, 2018
Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer
Bayer today announced that its collaboration partner Loxo Oncology, Inc., (NASDAQ: LOXO) has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug...
February 21, 2018
Bayer Announces Publication of Larotrectinib Data in The New England Journal of Medicine
Bayer and Loxo Oncology, Inc., (NASDAQ: LOXO) today announced the publication in The New England Journal of Medicine (NEJM) of larotrectinib data for pediatric and adult patients whose tumors...
February 07, 2018
Bayer to Feature Prostate Cancer Research at ASCO GU 2018 Symposium
Bayer announced today that research on Xofigo® (radium Ra 223 dichloride) injection and darolutamide, the company's investigational oral androgen receptor (AR) antagonist, in prostate cancer will...
January 17, 2018
Bayer to Highlight New Research at ASCO GI 2018 Cancer Symposium
Bayer announced today that new data from the continued research on Stivarga® (regorafenib) and Nexavar® (sorafenib) in advanced liver, colorectal and biliary tract cancers will be presented at...
December 20, 2017
Bayer Announces that Loxo Oncology, Inc., Initiates Rolling NDA Submission for Larotrectinib for the Treatment of TRK Fusion Cancers
Bayer today announced that its collaboration partner Loxo Oncology, Inc., (NASDAQ: LOXO) has initiated the submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug...
December 07, 2017
Bayer to Highlight New Research at ASH 2017
Bayer announced today that the latest findings from its growing body of research in hematologic malignancies for copanlisib and larotrectinib will be presented at the 59th Annual Meeting of the...
December 04, 2017
Updated larotrectinib pediatric Phase I clinical trial data demonstrates response in TRK fusion cancers
Bayer and Loxo Oncology, Inc., (NASDAQ: LOXO), today announced updated clinical data from the larotrectinib (LOXO-101) pediatric Phase I SCOUT trial (NCT02637687). These data are being presented...
November 30, 2017
Phase III trial of radium Ra 223 dichloride in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate cancer unblinded early
Bayer today announced that an Independent Data Monitoring Committee (IDMC) has recommended to unblind a Phase III trial of radium Ra 223 dichloride (radium-223) in combination with abiraterone...
November 24, 2017
Phase III study with Amikacin Inhale in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority
Bayer today announced that INHALE, a global Phase III clinical study program investigating Amikacin Inhale in addition to standard of care in intubated and mechanically ventilated patients with...
Want even more Bayer news?
Last Updated: March 26, 2018